<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management - children and young people | Management | Diabetes - type 1 | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the primary care management of children and young people with type 1 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers the primary care management of children and young people with type 1 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/diabetes-type-1/management/management-children-young-people/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management - children and young people | Management | Diabetes - type 1 | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/diabetes-type-1/management/management-children-young-people/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Diabetes - type 1</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management - children and young people</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/diabetes-type-1/","name":"Diabetes - type 1"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/diabetes-type-1/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management - children and young people"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Diabetes - type 1: </span><span>Scenario: Management of children and young people with type 1 diabetes</span></h1><p class="page-header__lead"><span>Last revised in November 2020</span></p></div><p class="visually-hidden">Covers the primary care management of children and young people with type 1 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Diabetes - type 1 chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adults"><a aria-current="false" href="../management-adults/index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adults</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - children and young people"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - children and young people</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initial-care-support">Initial care and support</a><ol aria-label="Sections within Initial care and support" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#care-plan">Care plan</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-3df">Basis for recommendation</a></li></ol></li><li><a href="index.html#insulin-therapy">Insulin therapy</a></li><li><a href="index.html#target-hba1c">Target HbA1c</a><ol aria-label="Sections within Target HbA1c" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-182">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-monitoring-of-blood-glucose">Self-monitoring of blood glucose</a><ol aria-label="Sections within Self-monitoring of blood glucose" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#target-glucose-self-monitoring-levels">Target glucose self-monitoring levels</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-c16">Basis for recommendation</a></li></ol></li><li><a href="index.html#lifestyle-management">Lifestyle management</a><ol aria-label="Sections within Lifestyle management" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#diet">Diet</a></li><li class=""><a href="index.html#exercise-physical-activity">Exercise and physical activity</a></li><li class=""><a href="index.html#alcohol-intake">Alcohol intake</a></li><li class=""><a href="index.html#smoking-substance-misuse">Smoking and substance misuse</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ab0">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-hypoglycaemia">Managing hypoglycaemia</a></li><li><a href="index.html#managing-suspected-diabetic-ketoacidosis">Managing suspected diabetic ketoacidosis</a><ol aria-label="Sections within Managing suspected diabetic ketoacidosis" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-806">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a><ol aria-label="Sections within Managing intercurrent illness" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#sick-day-rules">&#x27;Sick-day rules&#x27;</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ddd">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring-for-complications-of-type-1-diabetes">Monitoring for complications of type 1 diabetes</a><ol aria-label="Sections within Monitoring for complications of type 1 diabetes" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#psychological-social-problems">Psychological and social problems</a></li><li class=""><a href="index.html#eye-disease">Eye disease</a></li><li class=""><a href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a></li><li class=""><a href="index.html#diabetic-foot-problems">Diabetic foot problems</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f52">Basis for recommendation</a></li></ol></li><li><a href="index.html#transition-to-adult-care-services">Transition to adult care services</a><ol aria-label="Sections within Transition to adult care services" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-905">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-children-young-people" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-children-young-people" class="visually-hidden">Scenario: Management of children and young people with type 1 diabetes</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 358b4b43-73b1-45d5-adda-50dd5ad88ba2 --><!-- begin field f1a20d1f-bbf7-43d3-8256-acd900ad8738 --><p>From age 12 months to 17 years.</p><!-- end field f1a20d1f-bbf7-43d3-8256-acd900ad8738 --><!-- end item 358b4b43-73b1-45d5-adda-50dd5ad88ba2 --></div><section aria-labelledby="initial-care-support" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-care-support">What initial care and support should I offer a child or young person with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e384cf40-7a42-4347-afbe-87d37aa3bc8a --><!-- begin field d75678d7-8c2f-47fa-9c1a-1c1fd2056a15 --><ul><li><strong>Ensure that children and young people with type 1 diabetes are offered an <a class="topic-reference internal-reference" href="index.html#care-plan">ongoing integrated package of care</a> provided by a multidisciplinary paediatric diabetes team.</strong><ul><li>Ensure that the child or young person and/or their family/carers are involved in making decisions about their care. </li></ul></li><li><strong>Ensure that they are offered a continuing programme of education.</strong><ul><li>This should be tailored to the child/young person and include some <a class="topic-reference internal-reference" href="index.html#care-plan">core elements</a>.</li></ul></li><li><strong>Encourage children and young people with type 1 diabetes and/or their family/carers to:</strong><ul><li>Have the following immunizations recommended by the Department of Health (if applicable):<ul><li>Annual immunization against influenza (if aged over 6 months).</li><li>Immunization against pneumococcal infection.</li></ul></li><li>Wear or carry something that identifies them as having type 1 diabetes, for example:<ul><li>A MedicAlert® bracelet, necklace, or watch (available from <a data-hyperlink-id="4557d66a-78c4-4822-ad7b-a9310098380e" href="http://www.medicalert.org.uk/">www.medicalert.org.uk</a>).</li><li>Diabetes ID Card (available from <a data-hyperlink-id="666157db-7b2a-4148-9351-a93100983821" href="https://www.diabetes.co.uk/diabetic-products/medipal-card.html">www.diabetes.co.uk</a>).</li></ul></li><li>Discuss any concerns or questions with their diabetes specialist team.</li></ul></li><li><strong>Provide information and advice on:</strong><ul><li>Means and frequency of communicating with the paediatric diabetes team.<ul><li>Encourage children and young people with type 1 diabetes and/or their family/carers to attend clinic 4 times a year as regular contact is associated with optimal blood glucose control.</li><li>Ensure that the child or young person and/or their family/carers know how to contact the diabetes team during working hours and out of hours, as available.</li></ul></li><li>Government disability benefits — <a data-hyperlink-id="c27073d8-65e9-4541-9bfd-a931009af8b0" href="https://www.gov.uk/benefits-calculators">Benefits calculators</a> are available at <a data-hyperlink-id="b772f27c-eccd-4430-8910-abc80054af83" href="https://www.gov.uk/">www.gov.uk</a>.</li></ul></li><li><strong>Manage lifestyle issues,</strong> <strong>such as diet, exercise, and smoking. </strong>See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-management">Lifestyle management</a> for further information.</li><li><strong>Provide up-to-date information on diabetes support groups (local and national), </strong>including information on how to contact them and the benefits of membership.<ul><li>For example, the Diabetes UK website (<a data-hyperlink-id="55629234-95e2-4f9c-9d8b-abc800536bbf" href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>) has lots of information on <a data-hyperlink-id="24c6271b-4960-4266-b8b9-abc800536bda" href="https://www.diabetes.org.uk/guide-to-diabetes">Living with diabetes</a> and a <a data-hyperlink-id="ac1af5be-5314-4e40-a1c6-a931009cca2c" href="https://www.diabetes.org.uk/How_we_help/Talk-to-someone/Careline/">support helpline</a> for people with diabetes and their family/carers.</li><li>Provide this information at the time of diagnosis and periodically thereafter. Written information should also be available from the diabetes team.</li></ul></li></ul><!-- end field d75678d7-8c2f-47fa-9c1a-1c1fd2056a15 --><!-- end item e384cf40-7a42-4347-afbe-87d37aa3bc8a --></div><section aria-labelledby="care-plan" class="ChapterBody-module--wrapper--2HCfk "><h4 id="care-plan">Care plan for children and young people with type 1 diabetes</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 986edc43-035a-47d9-af47-37c86f58cd2d --><!-- begin field 1b34449f-17ce-47e5-9230-124ced62d80d --><ul><li><strong>At the time of diagnosis, children and young people with type 1 diabetes and/or their family/carers should be offered </strong><strong>an integrated package of care provided by </strong><strong>a multidisciplinary paediatric diabetes team. </strong><ul><li>To optimize the effectiveness of care and reduce the risk of complications, the diabetes team should include members with appropriate training in clinical, educational, dietetic, lifestyle, mental health, and foot care aspects of diabetes for children and young people.</li><li>The child or young person may be offered home-based or inpatient management, depending on clinical need and family circumstances and wishes. <ul><li>Home-based care with support from the local paediatric diabetes team (including 24-hour telephone access) is safe and as effective as inpatient initial management.</li><li>Initial inpatient management may be offered to children younger than 2 years of age; children and young people with social or emotional factors that would make home-based management inappropriate; and children and young people who live far away from the hospital.</li></ul></li></ul></li><li><strong>They should also be offered a continuing programme of education.</strong> This should:<ul><li>Include the following core elements:<ul><li>Insulin therapy, including its aims, how it works, its mode of delivery, and dosage adjustment.</li><li>Blood glucose monitoring, including targets for blood glucose control (blood glucose and HbA1c levels).</li><li>The effects of diet, physical activity, and intercurrent illness on blood glucose control.</li><li>Managing intercurrent illness ('sick-day rules', including monitoring of blood ketones).</li><li>Detecting and managing hypoglycaemia, hyperglycaemia, and ketosis.</li></ul></li><li>Be tailored to the child/young person and/or their family/carers, taking account of issues such as:<ul><li>Emotional wellbeing.</li><li>Age and maturity.</li><li>Cultural considerations.</li><li>Existing knowledge.</li><li>Current and future social circumstances.</li><li>Life goals.</li></ul></li></ul></li></ul><!-- end field 1b34449f-17ce-47e5-9230-124ced62d80d --><!-- end item 986edc43-035a-47d9-af47-37c86f58cd2d --></div></section><section aria-labelledby="basis-for-recommendation-3df" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-3df">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3dfee761-e8e5-45da-a7f1-baa4edda3e03 --><!-- begin field 03712008-cad8-4dee-a8a0-e4dd9bdbcb9b --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng18/evidence/full-guideline-pdf-435396352" data-hyperlink-id="a80a94c2-5ad3-4d5d-9aaa-a93100c4866c">full NICE guideline</a>.</p><h5>Ongoing package of care provided by a multidisciplinary team</h5><ul><li>Type 1 diabetes can have a potentially devastating effect on a child or young person and their family/carers, and the management, education, empowerment, and support offered in the first few weeks can have a long-term effect on their acceptance of the condition and their skills and motivation in its ongoing management.</li><li>An ongoing package of care is recommended by NICE based on the expert opinion and experience of the NICE guideline development group (GDG). </li></ul><h5>Continuing programme of education </h5><ul><li>In adults with type 1 diabetes, NICE recommends a structured educational programme, such as the dose adjustment for normal eating (DAFNE) programme, as it has been shown to be effective.</li><li>However, for the management of children and young people with type 1 diabetes, the available evidence did not consistently demonstrate that structured education was more effective than other types of educational packages for outcomes such as:<ul><li>Reducing HbA1c, episodes of severe hypoglycaemia, or the risk of diabetic ketoacidosis.</li><li>Improving adherence to diabetes management, health-related quality of life, or adherence to the educational intervention.</li><li>Satisfaction among children and young people or their parents and carers. </li></ul></li><li>Nevertheless, the NICE GDG emphasized that some education is essential for children and young people with type 1 diabetes and their families/carers to enable them to manage this life-long condition. Therefore, a continuing programme of education should be offered from diagnosis.</li><li>Regarding an individualized approach, the NICE GDG noted that contact with families/carers of children and young people with type 1 diabetes supports the belief that people differ in their educational needs and learning styles. For this reason, the GDG recommends that although the education should cover certain key points, the timing and approach to delivery should be individualized. </li></ul><h5>Additional advice to the child or young person and/or their family/carers</h5><ul><li>The recommendations on attending clinic, immunization, discussing concerns and questions, carrying an identification card/jewellery, and support groups are based on the NICE guideline.<ul><li>NICE based the recommendation on immunizations on advice issued in the <a href="https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book" data-hyperlink-id="6d6f996d-1f65-443c-ae3c-a93100c486d3">Green Book</a> published by Public Health England (PHE).</li><li>All other recommendations are based on the available evidence as well as the expert opinion and experience of the NICE GDG.</li></ul></li></ul><!-- end field 03712008-cad8-4dee-a8a0-e4dd9bdbcb9b --><!-- end item 3dfee761-e8e5-45da-a7f1-baa4edda3e03 --></div></section></section><section aria-labelledby="insulin-therapy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="insulin-therapy">Insulin therapy for children and young people with type 1 diabetes</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 74a21b4d-6cd3-4280-9f4c-abe601464833 --><!-- begin field 6591018f-be16-4dda-8211-abe60146485c --><ul><li><strong>Insulin therapy should only be initiated and managed by healthcare professionals with the relevant expertise and training. </strong></li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for detailed information on insulin therapy, including available insulin preparations, recommended regimens, information on injection technique and injection sites, storage of insulin, adverse effects, safety issues, and general information on lifestyle and cultural aspects of insulin treatment (such as driving whilst on insulin treatment, fasting, shift work, holiday and travel, and insurance).</li></ul><!-- end field 6591018f-be16-4dda-8211-abe60146485c --><!-- end item 74a21b4d-6cd3-4280-9f4c-abe601464833 --></div></section><section aria-labelledby="target-hba1c" class="ChapterBody-module--wrapper--2HCfk "><h3 id="target-hba1c">What is the target HbA1c for children and young people with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fcd9ca78-84b5-46e4-b535-9008ae900970 --><!-- begin field 0681c1a3-9788-4de7-b624-9fa6899dc709 --><ul><li><strong>Explain to children and young people with type 1 diabetes and/or their family/carers that an HbA1c target level of 48 mmol/mol (6.5%) or lower is ideal to minimize the risk of long-term <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of type 1 diabetes. </strong><ul><li>Explain the benefits of safely achieving and maintaining the lowest attainable HbA1c.<ul><li>If the child or young person has an HbA1c level above the ideal target, explain that any reduction in HbA1c level reduces the risk of long-term complications.</li></ul></li><li>Agree an individualized lowest achievable HbA1c target with each child or young person with type 1 diabetes and/or their family/carers, taking into account factors such as daily activities, individual life goals, complications, comorbidities, and the risk of hypoglycaemia (generally defined as blood glucose levels less than 3.5 mmol/L).<ul><li>Support them to safely achieve and maintain their individually agreed HbA1c target level.</li><li>Ensure that children and young people with type 1 diabetes are offered measurement of their HbA1c level 4 times a year. More frequent testing may be appropriate if there is concern about suboptimal blood glucose control.</li></ul></li></ul></li></ul><!-- end field 0681c1a3-9788-4de7-b624-9fa6899dc709 --><!-- end item fcd9ca78-84b5-46e4-b535-9008ae900970 --></div><section aria-labelledby="basis-for-recommendation-182" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-182">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 18243c7d-c603-4d86-8a7e-e8b0780da32b --><!-- begin field 52476d86-ba14-4683-aced-cdad21e71b8f --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng18/evidence/full-guideline-pdf-435396352" data-hyperlink-id="a80a94c2-5ad3-4d5d-9aaa-a93100c4866c">full NICE guideline</a>.</p><h5>Measuring HbA1c</h5><ul><li><p>HbA1c (glycated haemoglobin) develops when haemoglobin joins with glucose in the blood, becoming ‘glycated’. By measuring HbA1c, healthcare professionals can get an overall picture of what a person's average blood glucose levels have been over 2–3 months. The higher the HbA1c, the greater the risk of developing diabetes-related complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">WHO, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Diabetes.co.uk, 2019</a>].</p></li></ul><h5>Optimal HbA1c target</h5><ul><li>NICE did not identify any evidence on the optimal HbA1c target for children and young people with type 1 diabetes. However, the NICE guideline development group (GDG) agreed that targets should aim to minimize the risk of long-term complications without incurring an increased risk of hypoglycaemic episodes.</li><li>Based on evidence in adults with type 1 diabetes and the consensus of the GDG, NICE recommends an overall target of 48 mmol/mol (6.5%) where possible for children and young people with type 1 diabetes.</li><li>The GDG noted that this recommended target is lower than previous recommendations for children and young people (which was an HbA1c level of less than 58 mmol/mol [7.5%]) but emphasized that the result of the change would be to reduce the risk of long-term complications of type 1 diabetes in a population that will have a long duration of diabetes because the condition starts before adulthood. The GDG also felt that aligning the recommended targets with that of adults with type 1 diabetes would assist with transition from paediatric to adult services.</li><li>Recognizing that this target may not be achieved in every case, NICE recommends providing reassurance for children and young people and/or their family/carers that targets should be individualized to take account of personal circumstances.</li></ul><!-- end field 52476d86-ba14-4683-aced-cdad21e71b8f --><!-- end item 18243c7d-c603-4d86-8a7e-e8b0780da32b --></div></section></section><section aria-labelledby="self-monitoring-of-blood-glucose" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-monitoring-of-blood-glucose">What should I advise on self-monitoring of blood glucose?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 112823b4-9c13-4d8b-9730-abe6014636af --><!-- begin field e62fe354-bff9-46f8-be65-abe6014636f0 --><ul><li>​​​​​​<strong>Self-monitoring of blood glucose refers to home blood glucose testing for people with diabetes to determine the amount of glucose in the blood at any given time. </strong><ul><li>To self-monitor, the person would need a blood glucose monitor, lancets (which fit into a finger-pricking device), and testing strips (on which the blood is collected for testing in the machine).</li><li>See the section on <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">Target glucose self-monitoring levels</a> for information on blood glucose self-monitoring target levels.</li></ul></li><li><strong>Self-monitoring skills should be taught at the time of diagnosis and at the time of initiation of insulin therapy, and should be reviewed at least annually. </strong>The review should include checking that the person knows:<ul><li>How to use their blood glucose monitoring meter — this can be done by asking them to demonstrate their technique.</li><li>When to test — for example before breakfast and 2 hours after meals, during periods of illness, before driving, and if they feel hypoglycaemic. </li><li>How to assess and respond to test results, including how to:<ul><li>Interpret trends in blood glucose levels as well as individual readings — this is important for adjusting insulin doses.</li><li>Identify the causes of high and low blood glucose values.</li></ul></li></ul></li><li><strong>Continuous glucose monitoring is a way of measuring glucose levels continuously throughout the day and night via a tiny electrode inserted under the skin. </strong><ul><li>Continuous glucose monitoring systems provide continuous measurements (every 1–5 minutes) of glucose concentrations in the interstitial fluid, which correlate with blood glucose levels. It can provide both retrospective and real-time information to detect hypoglycaemic and hyperglycaemic episodes, predict impending hypoglycaemia, and detect wide fluctuations in glucose levels (glycaemic variability).</li><li>Continuous glucose monitoring is not routinely recommended for children and young people with type 1 diabetes but may be considered in <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">certain circumstances</a>, for example in children and young people with frequent severe hypoglycaemia.</li></ul></li></ul><!-- end field e62fe354-bff9-46f8-be65-abe6014636f0 --><!-- end item 112823b4-9c13-4d8b-9730-abe6014636af --></div><section aria-labelledby="target-glucose-self-monitoring-levels" class="ChapterBody-module--wrapper--2HCfk "><h4 id="target-glucose-self-monitoring-levels">What are the target blood glucose self-monitoring levels for children and young people with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 79eae28b-b46d-411e-9968-abee00d1f178 --><!-- begin field 23acf83d-eef6-4db5-a2b0-abee00d1f1c6 --><ul><li><strong>For children and young people with type 1 diabetes, advise routine <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring of blood glucose</a> levels by performing at least five capillary blood glucose tests per day. </strong><ul><li>Advise the child or young people and/or their family/carers that more frequent testing is often needed (for example with physical activity and during intercurrent illness), and ensure they have enough test strips for this. </li><li>Offer a choice of equipment for monitoring capillary blood glucose so that they can optimize their blood glucose control in response to adjustment of insulin, diet, and exercise. </li></ul></li><li><strong>The optimal targets for glucose self-monitoring in children and young people with type 1 diabetes are: </strong><ul><li>Fasting plasma glucose level of 4–7 mmol/L on waking.</li><li>Plasma glucose level of 4–7 mmol/L before meals at other times of the day.</li><li>Plasma glucose level of 5–9 mmol/L after meals.</li><li>For young people of driving age, plasma glucose level of at least 5 mmol/L when driving.</li></ul></li><li><strong>Explain that achieving and maintaining blood glucose levels towards the lower end of the target optimal ranges will help them to achieve the lowest attainable HbA1c.</strong><ul><li>Ensure that children and young people do not experience problematic hypoglycaemia or undue emotional distress when achieving, or attempting to achieve, blood glucose targets. </li><li>Be aware that there may be conflict between the child or young person and their family members or carers about blood glucose targets and that an agreed compromise may be needed.</li><li>Explain that blood glucose levels should be interpreted in the context of the 'whole child', which includes the social, emotional, and physical environment. </li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">Continuous glucose monitoring</a> is not currently recommended for all children and young people with type 1 diabetes.</strong> The National Institute for Health and Care Excellence (NICE) recommends that:<ul><li>Ongoing real-time continuous glucose monitoring with alarms may be offered to children and young people with type 1 diabetes who have one or more of the following:<ul><li>Frequent severe hypoglycaemia.</li><li>Impaired awareness of hypoglycaemia associated with adverse consequences (for example seizures or anxiety).</li><li>Inability to recognize, or communicate about, symptoms of hypoglycaemia (for example because of cognitive or neurological disabilities).</li></ul></li><li>Ongoing real-time continuous glucose monitoring may be considered for:<ul><li>Neonates, infants, and pre-school children.</li><li>Children and young people who undertake high levels of physical activity (for example sport at a regional, national, or international level).</li><li>Children and young people who have comorbidities (for example anorexia nervosa) or who are receiving treatments (for example corticosteroids) that can make blood glucose control difficult.</li></ul></li><li>Intermittent (real-time or retrospective) continuous glucose monitoring may be considered to help improve blood glucose control in children and young people who continue to have hyperglycaemia despite insulin adjustment and additional support.</li></ul></li></ul><!-- end field 23acf83d-eef6-4db5-a2b0-abee00d1f1c6 --><!-- end item 79eae28b-b46d-411e-9968-abee00d1f178 --></div></section><section aria-labelledby="basis-for-recommendation-c16" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-c16">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c162948c-2d5d-4f79-86e7-abe6014636f2 --><!-- begin field b083ec90-421d-4d2d-8feb-abe6014636f2 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng18/evidence/full-guideline-pdf-435396352" data-hyperlink-id="a80a94c2-5ad3-4d5d-9aaa-a93100c4866c">full NICE guideline</a>.</p><h5>Optimal blood glucose targets</h5><ul><li>NICE did not identify any evidence for inclusion in the 2015 diabetes guideline update review, but the guideline development group (GDG) agreed that tighter blood glucose control than recommended in the 2004 diabetes guideline (which was pre-prandial blood glucose level of 4–8 mmol/L and a post-prandial level of less than 10 mmol/L) would be beneficial.</li><li>There was a shared feeling within the group that it was beneficial to established tight control as early as possible (preferably from diagnosis), and the group felt that lower targets were particularly beneficial for children and young people with type 1 diabetes.</li><li>The GDG noted the importance of setting targets that the child or young person could live with and that if the targets set were too narrow then they would become difficult to comply with.</li><li>The GDG agreed that it was generally important to update the guidance for children and young people to be consistent with the guidance for adults. In certain circumstances, however, the targets should be slightly different, specifically with regard to the target range for fasting blood glucose.</li></ul><h5>Frequency and timing of self-monitoring of blood glucose</h5><ul><li>Overall, evidence identified by NICE showed an inverse correlation between the frequency of capillary blood glucose monitoring and HbA1c such that as frequency of capillary blood glucose monitoring increased then HbA1c improved. The quality of the evidence for this finding was low.</li><li>One study showed that a higher incidence of severe hypoglycaemic episodes was associated with more frequent capillary blood glucose monitoring. </li></ul><h5>Real-time continuous glucose monitoring</h5><ul><li>The NICE GDG acknowledged that the majority of the evidence identified in the review for continuous glucose monitoring compared with capillary blood glucose monitoring did not clearly support the use of one monitoring strategy over the other. The only prioritized outcome for which continuous glucose monitoring was found to be more beneficial than capillary blood glucose monitoring was parental satisfaction with the intervention.</li><li>Although the evidence was not particularly compelling, based on their experience the NICE GDG felt that continuous glucose monitoring enabled children and young people with type 1 diabetes and/or their family/carers to be more responsive to subtle changes in blood glucose concentrations and therefore this monitoring strategy was likely to produce clinical benefits in terms of glycaemic control in the certain children and young people with type 1 diabetes, for example those with frequent hypoglycaemia.</li><li>The GDG acknowledged that continuous glucose monitoring (real-time or otherwise) is generally more costly than capillary blood glucose monitoring. Nevertheless, the group felt that in light of the potential benefits to the specific subgroups of children and young people identified, the use of real-time continuous glucose monitoring would represent a cost-effective use of NHS resources. They also noted there may be some associated savings in terms of prevention of adverse effects from poor control and reduced need for capillary blood glucose testing strips (with continuous glucose monitoring, capillary blood testing is needed only for calibrating the continuous glucose monitoring device).</li><li>The definition of continuous glucose monitoring is taken from review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Edelman, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ajjan, 2019</a>].</li></ul><!-- end field b083ec90-421d-4d2d-8feb-abe6014636f2 --><!-- end item c162948c-2d5d-4f79-86e7-abe6014636f2 --></div></section></section><section aria-labelledby="lifestyle-management" class="ChapterBody-module--wrapper--2HCfk "><h3 id="lifestyle-management">How should I manage lifestyle issues in children and young people with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a3d7e5cf-d3bd-451b-845f-3566283e7e37 --><!-- begin field a082ddc1-842c-488f-996d-6180bfd7420a --><ul><li><strong>See the sections on <a class="topic-reference internal-reference" href="index.html#diet">Diet</a>, <a class="topic-reference internal-reference" href="index.html#exercise-physical-activity">Exercise</a>, <a class="topic-reference internal-reference" href="index.html#alcohol-intake">Alcohol</a>, and <a class="topic-reference internal-reference" href="index.html#smoking-substance-misuse">Smoking and substance misuse</a> for information on managing these lifestyle issues.</strong></li><li>Detailed information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, and shift work, are covered in the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#lifestyle-cultural-issues">Additional information and advice</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a>.</li></ul><!-- end field a082ddc1-842c-488f-996d-6180bfd7420a --><!-- end item a3d7e5cf-d3bd-451b-845f-3566283e7e37 --></div><section aria-labelledby="diet" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diet">Advice on diet</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bb6e7b29-9b2f-460f-8ae5-d5599d86add9 --><!-- begin field f7b8494d-fecb-485e-825a-3b249359deff --><ul><li><strong>Support children and young people with type 1 diabetes and/or their family/carers</strong><strong> to develop a good working knowledge of nutrition and how it affects their diabetes. </strong><ul><li>Explain how healthy eating, including eating foods with a low glycaemic index (GI), at least five portions of fruit and vegetables a day, and appropriate types and amounts of fats, can reduce their risk of cardiovascular disease (CVD).</li><li>Explain that a low GI diet may also help to improve blood glucose control and reduce the risk of hyperglycaemic episodes.</li><li>Support the child or young person and their family/carers to adjust their food choices accordingly, or consider referring them to a paediatric dietitian.<ul><li>Offer level 3 carbohydrate-counting education (carbohydrate counting with adjustment of insulin dosage according to an insulin:carbohydrate ratio) to children and young people who are using a multiple daily insulin injection regimen or continuous subcutaneous insulin infusion (CSII or insulin pump) therapy. Repeat the offer at intervals thereafter.</li><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#recommended-insulin-regimen">Insulin regimens</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for information on insulin treatment regimens.</li></ul></li><li>Explain that children and young people with type 1 diabetes have the same basic nutritional needs as other children and young people so their food should provide sufficient energy and nutrients for optimal growth and development.</li><li>If necessary, offer the child or young person dietetic support to help optimize body weight.</li></ul></li><li><strong>Take into account social and cultural considerations</strong> <strong>when providing advice on dietary management to children and young people with type 1 diabetes.</strong></li></ul><!-- end field f7b8494d-fecb-485e-825a-3b249359deff --><!-- end item bb6e7b29-9b2f-460f-8ae5-d5599d86add9 --></div></section><section aria-labelledby="exercise-physical-activity" class="ChapterBody-module--wrapper--2HCfk "><h4 id="exercise-physical-activity">Advice on exercise and physical activity</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c47e0c46-29e7-4b0c-85c6-b80e08cbac1f --><!-- begin field b015ac40-e639-4ad9-8bc3-19adaac3ae6b --><ul><li><strong>Advise children and young people with type 1 diabetes and/or their family/carers that regular exercise may lower glucose levels, </strong><strong>as exercise increases the amount of glucose used by the muscles for energy.</strong><ul><li>Explain that:<ul><li>They can take part in all forms of exercise, provided appropriate attention is given to diet and changes in insulin.</li><li>Changes in daily exercise patterns may require insulin dose and/or carbohydrate intake to be altered.</li></ul></li><li>Offer advice on the effects of exercise on blood glucose levels, and advise on strategies for avoiding hypo- or hyperglycaemia during or after physical activity. For example:<ul><li>Additional carbohydrate should be consumed as appropriate to avoid hypoglycaemia.</li><li>Carbohydrate-based foods should be readily available during and after exercise.</li><li>Additional carbohydrate should be consumed if plasma glucose levels are less than 7 mmol/L before exercise is undertaken.</li><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-an-episode-of-hypoglycaemia">Managing hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for information on managing a hypoglycaemic episode.</li></ul></li><li>Encourage them to monitor blood glucose levels before and after exercise so that they can:<ul><li>Identify when changes in insulin or food intake are necessary.</li><li>Learn the blood glucose response to different exercise conditions.</li><li>Be aware of exercise-induced hypoglycaemia (which may occur several hours after prolonged exercise).</li></ul></li></ul></li><li><strong>Also advise that:</strong><ul><li>Regular exercise can reduce the risk of cardiovascular disease in the long term.</li><li>Exercise can help with weight management (when combined with a healthy diet). See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li><li>They should seek advice from their diabetes team if they wish to participate in a sport that may have particular risks for people with diabetes. Additional information may be available from local and/or national support groups and organizations, such as Diabetes UK (<a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/" data-hyperlink-id="2b691721-b976-40e6-ad43-a93100c45884">www.diabetes.org.uk</a>).</li></ul></li><li><strong>The current <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/832868/uk-chief-medical-officers-physical-activity-guidelines.pdf" data-hyperlink-id="2563ca7e-8685-4f1d-9b4b-abc600897a4c">UK Chief Medical Officers' Physical Activity Guidelines</a> state that:</strong><ul><li><strong>Toddlers (1–2 years) should:</strong><ul><li>Spend at least 180 minutes per day in a variety of physical activities at any intensity, including active and outdoor play, spread throughout the day.</li></ul></li><li><strong>Children aged 3–4 years should:</strong><ul><li>Spend at least 180 minutes per day in a variety of physical activities spread throughout the day, including active and outdoor play. The 180 minutes should include at least 60 minutes of moderate-to-vigorous intensity physical activity.</li></ul></li><li><strong>Children and young people aged 5–18 years should:</strong><ul><li>Engage in moderate-to-vigorous intensity physical activity for an average of at least 60 minutes per day across the week. This can include all forms of activity, such as physical education, active travel, after-school activities, play, and sports.</li><li>Engage in a variety of types and intensities of physical activity across the week to develop movement skills, muscular fitness, and bone strength.</li><li>Aim to minimize the amount of time spent being sedentary. When physically possible, they should break up long periods of not moving with at least light physical activity.</li></ul></li></ul></li></ul><!-- end field b015ac40-e639-4ad9-8bc3-19adaac3ae6b --><!-- end item c47e0c46-29e7-4b0c-85c6-b80e08cbac1f --></div></section><section aria-labelledby="alcohol-intake" class="ChapterBody-module--wrapper--2HCfk "><h4 id="alcohol-intake">Advice on alcohol intake</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c02f3d88-6a07-4fab-9421-1c6fe40d6a9c --><!-- begin field 409906ca-0a98-41f9-83fc-ba6e730c492c --><ul><li><strong>Remind young people and/or their family/carers that the legal drinking age in the UK is 18 years.</strong></li><li><strong>Advise young people with type 1 diabetes who drink:</strong><ul><li>To avoid drinking alcohol on an empty stomach as the alcohol will be absorbed faster. They should:<ul><li>Eat a snack that contains carbohydrate (such as a sandwich or crisps) before and after drinking alcohol. Extra insulin is not required.</li><li>Measure their blood glucose regularly, and maintain their blood glucose with appropriate carbohydrate intake.</li></ul></li><li>That alcohol may exacerbate or prolong the hypoglycaemic effect of insulin, including nocturnal hypoglycaemia.<ul><li>Signs of hypoglycaemia may become less clear, and delayed hypoglycaemia may occur (which can be hours after alcohol consumption).</li><li>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-hypoglycaemia">Hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for detailed information on hypoglycaemia.</li></ul></li><li>To always wear some form of diabetes identification (as the reduced awareness of hypoglycemia may be confused with alcohol intoxication). Examples of diabetes identification include:<ul><li>A MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="4557d66a-78c4-4822-ad7b-a9310098380e">www.medicalert.org.uk</a>).</li><li>Diabetes ID Card (available from <a href="https://www.diabetes.co.uk/diabetic-products/medipal-card.html" data-hyperlink-id="75db92f1-6a21-421c-8aac-abf6016c73a6">www.diabetes.co.uk</a>).</li></ul></li></ul></li><li><strong>Give information on the recommended maximum alcohol intake.</strong><ul><li>The <a href="http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/545739/GDG_report-Jan2016.pdf" data-hyperlink-id="633e12bc-4c45-49d1-912a-abf60119588e">Chief Medical Officers' guideline</a> for both men and women states that:<ul><li>It is safest not to regularly drink more than 14 units of alcohol per week, to keep health risks from drinking alcohol to a low level.</li><li>People who drink as much as 14 units of alcohol per week should spread this evenly over 3 days or more. One or two heavy drinking sessions increases the risk of death from long-term illnesses and from accidents and injuries.</li><li>The risk of developing a range of illnesses (such as cancers of the mouth, throat, and breast) increases with any amount of alcohol consumed on a regular basis.</li><li>If people wish to cut down the amount of alcohol they are drinking, a good way to help achieve this is to have several drink-free days each week.</li><li>For women who are pregnant or planning a pregnancy, the safest approach is not to drink alcohol at all, to keep risks to the baby to a minimum.</li></ul></li><li>See the section on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/background-information/definition/index.html#unit-of-alcohol">Unit of alcohol</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a> for more information on alcohol units.</li><li>Information on <a href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/what-to-drink-with-diabetes/Alcohol-and-diabetes" data-hyperlink-id="c9397b2f-dde1-4e5f-9628-abc60085776e">Alcohol and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/young-adults/type-1-drinking" data-hyperlink-id="33645533-969d-4624-b53b-abc6008dfa2d">Type 1 diabetes and drinking</a> are also available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/" data-hyperlink-id="34be83a3-1ff2-4ea8-adf7-abc600857a1f">www.diabetes.org.uk</a>).</li></ul></li></ul><!-- end field 409906ca-0a98-41f9-83fc-ba6e730c492c --><!-- end item c02f3d88-6a07-4fab-9421-1c6fe40d6a9c --></div></section><section aria-labelledby="smoking-substance-misuse" class="ChapterBody-module--wrapper--2HCfk "><h4 id="smoking-substance-misuse">Advice on smoking and substance misuse</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f166712e-3690-41f6-9c37-7940620172f0 --><!-- begin field b86a72dd-94a0-48b6-9722-ea27a511a39d --><ul><li><strong>Explain about general health problems associated with smoking, particularly the risks of developing vascular complications.</strong><ul><li>Encourage children and young people with type 1 diabetes not to start smoking.</li><li>Offer smoking cessation programmes to those who smoke. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li></ul></li><li><strong>Explain about the general dangers of substance misuse and the possible effects on blood glucose control.</strong><ul><li>Information, advice, and support on substance misuse are available on the Talk to Frank website (<a href="http://www.talktofrank.com/" data-hyperlink-id="e3f1bf10-9796-4e76-806b-a93100a4c7a6">www.talktofrank.com</a>).</li></ul></li></ul><!-- end field b86a72dd-94a0-48b6-9722-ea27a511a39d --><!-- end item f166712e-3690-41f6-9c37-7940620172f0 --></div></section><section aria-labelledby="basis-for-recommendation-ab0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ab0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ab057f04-982a-41cd-ba13-58f8ed167bcd --><!-- begin field d3f552cd-cab7-430c-924d-14a72eb682b7 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng18/evidence/full-guideline-pdf-435396352" data-hyperlink-id="a80a94c2-5ad3-4d5d-9aaa-a93100c4866c">full NICE guideline</a>.</p><h5>Advice on diet</h5><ul><li>NICE based the general dietary recommendations for children and young people with type 1 diabetes on national and international guidelines on the management of diabetes in adults due to limited evidence and the lack of UK dietary guidelines on the optimal diet and nutritional requirements for children and young people with type 1 diabetes.</li><li>The guideline development group (GDG) agreed that if the use of a particular dietary regimen resulted in a reduction in HbA1c by near to (or greater than) 5.5 mmol/mol (0.5%), this would represent an important clinical benefit.</li><li>For low glycaemic index (GI) diets:<ul><li>The GDG was aware of a Cochrane systematic review that provided strong evidence of improved blood glucose control (reduction in HbA1c by 5.5 mmol/mol plus a reduction in hypoglycaemic episodes) in a mixed population that predominantly included adults with type 2 diabetes who were following a low GI diet. Based on physiological principles, the GDG believed that similar benefits would be expected in children and young people with type 1 diabetes.</li><li>Bearing in mind that a low GI diet could also potentially be an unhealthy one, as some low GI foods (such as pizza) are high in fat, the GDG recommended that appropriate nutritional advice should be given to the child or young person and/or their parents/carers.</li></ul></li><li>For carbohydrate counting:<ul><li>Trial evidence did not show improvements in HbA1c at 12 or 24 months that met the GDG's predefined threshold for a minimally important difference (5.5 mmol/mol [0.5%]) or caused a statistically significant improvement in HbA1c. However, there was a trend towards improvement with a mean difference of 0.3%, which was consistent with the group’s expectations.</li><li>Based on the clinical experience of the GDG and the fact that dietary advice based on carbohydrate counting combined with multiple daily injections more closely resembles normal physiological processes than diet and insulin regimens based on prescribed eating patterns, the GDG concluded that it was beneficial to offer level 3 carbohydrate counting to children and young people using multiple daily injections (insulin pump therapy).  </li><li>This conclusion was supported by the GDG's clinical consensus that a variation in carbohydrate intake of as little as 10 g could result in a measurable difference in blood glucose when using a fixed dose of insulin. </li></ul></li></ul><h5>Advice on alcohol intake</h5><ul><li>Although it is illegal for people under the age of 18 years to buy alcohol, the NICE GDG recognized that alcohol consumption in young people can be a problem.</li><li>NICE did not find any evidence investigating the effects of alcohol consumption in young people with type 1 diabetes, but the GDG noted that it has been widely reported in discussion articles that drinking alcohol can cause an increased risk of hypoglycaemia in people with type 1 diabetes. </li><li>In the absence of trial evidence, NICE based the recommendations on alcohol on advice in the <em>I</em><em>SPAD consensus guidelines for the management of type 1 diabetes mellitus in children and adolescents</em> published by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ISPAD, 2000</a>], which has been updated [<a class="bibliography-reference internal-reference" href="../../references/index.html">ISPAD, 2018</a>], and on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/" data-hyperlink-id="b33ef866-856c-4f53-9434-abc80061b022">www.diabetes.org.uk</a>).</li></ul><h5>Advice on exercise</h5><ul><li>NICE found limited evidence on the effects of exercise in children and young people with type 1 diabetes. </li><li>However, the GDG noted that, in general, the advantages of exercise relate more to cardioprotective effects and psychological wellbeing than to improvements in blood glucose control. In addition, clinical experience shows that exercise in children and young people with type 1 diabetes can lead to metabolic disturbances, occasionally leading to hyperglycaemia, ketosis or, more frequently, hypoglycaemia. </li><li>The GDG concluded that exercise should be encouraged in all young people with type 1 diabetes. However, understanding the glycaemic response to different types of exercise and to changes in insulin and dietary management is essential for optimal blood glucose control and prevention of exercise-induced hypoglycaemia.</li></ul><h5>Advice on smoking</h5><ul><li>Evidence identified by NICE showed that:<ul><li>Smoking causes excess morbidity and mortality.</li><li>The risk of morbidity and mortality among smokers with type 1 diabetes is greater than would be expected from simply combining the risks of smoking and type 1 diabetes. </li><li>Macrovascular complications are increased in young adults with type 1 diabetes who smoke compared with those who do not.</li></ul></li></ul><h5>Advice on substance misuse</h5><ul><li>NICE found little published information on the effects of substance misuse in children and young people with type 1 diabetes.</li><li>This recommendation is therefore based on the expert opinion of the NICE GDG, who considered the well-known effects of substance misuse in the general population.</li></ul><!-- end field d3f552cd-cab7-430c-924d-14a72eb682b7 --><!-- end item ab057f04-982a-41cd-ba13-58f8ed167bcd --></div></section></section><section aria-labelledby="managing-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-hypoglycaemia">How should I manage a child or young person hypoglycaemia?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 35462f95-b3cc-4895-8f48-13d4f15a0d3a --><!-- begin field 63534772-a642-4de7-919d-f39a9bceeb99 --><p>See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-hypoglycaemia">Hypoglycaemia</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for information on how to manage hypoglycaemia.</p><!-- end field 63534772-a642-4de7-919d-f39a9bceeb99 --><!-- end item 35462f95-b3cc-4895-8f48-13d4f15a0d3a --></div></section><section aria-labelledby="managing-suspected-diabetic-ketoacidosis" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-suspected-diabetic-ketoacidosis">How should I manage a child or young person with diabetic ketoacidosis?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 75ff36d7-b727-47ce-8523-1bd391819eb3 --><!-- begin field e9da7ab2-c290-4e31-b0a3-4d78cc006739 --><ul><li><strong>If diabetic ketoacidosis (DKA) is <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">suspected</a> in a child or young person, </strong>arrange immediate admission to a hospital with acute paediatric facilities, for confirmation of the diagnosis and emergency treatment with intravenous insulin and fluids. </li><li><strong>After a child or young person has recovered from an episode of DKA:</strong><ul><li>Discuss with them and/or their family/carers the <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">factors</a> that may have led to the episode.<ul><li>If DKA is recurrent, consider the possibility of non-adherence to treatment or intentional insulin omission in order to lose weight (<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a>).</li><li>Assess the emotional and psychological wellbeing of children and young people with type 1 diabetes who present with frequent episodes of DKA. </li></ul></li><li>Give general information on DKA, including information on how to reduce the risk of future episodes.<ul><li>Encourage the child or young person and/or their family/carers to attend diabetes clinic regularly (4 times per year) as this is associated with good glucose control.</li><li>Information on DKA for people with type 1 diabetes and their family/carers is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/diabetic_ketoacidosis" data-hyperlink-id="a5ee0da5-1c79-4f79-b0d2-a9310098c826">www.diabetes.org.uk</a>).</li></ul></li><li>Ensure that the child or young person and/or their family/carer have appropriate information on how to manage diabetes during a period of illness (<a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a>). </li></ul></li></ul><!-- end field e9da7ab2-c290-4e31-b0a3-4d78cc006739 --><!-- end item 75ff36d7-b727-47ce-8523-1bd391819eb3 --></div><section aria-labelledby="basis-for-recommendation-806" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-806">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 80656ecb-1d79-4136-a96d-7a9e0d9b81ed --><!-- begin field 2d27cb99-dba3-44d6-a347-54edd7c2974a --><ul><li>Diabetic ketoacidosis (DKA) is a medical emergency. It has a high mortality rate if it is not managed promptly with close monitoring and careful correction of fluid and electrolyte imbalances [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint British Diabetes Societies Inpatient Care Group, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Karslioglu French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BSPED, 2020</a>].</li><li>The recommendation to admit children and young people with suspected DKA and the advice on how to manage the person after an episode of DKA are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li><li>A <a href="http://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/2017-08/Diabulimia%20Position%20statement%20Mar%202017.doc" data-hyperlink-id="597277af-e86d-4b8e-b215-abe90097b83b">position statement</a> issued by Diabetes UK lists recurrent DKA and recurrent hospital admission for hyperglycaemia as possible signs of <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a> (a 'disordered eating behaviour' in the practice of reducing or omitting insulin in order to lose weight).</li></ul><!-- end field 2d27cb99-dba3-44d6-a347-54edd7c2974a --><!-- end item 80656ecb-1d79-4136-a96d-7a9e0d9b81ed --></div></section></section><section aria-labelledby="managing-intercurrent-illness" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-intercurrent-illness">How should I manage a child or young person with type 1 diabetes during a period of illness?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1ff2eab3-60fc-45b8-addc-c8a938d90a94 --><!-- begin field a3dd2a9a-f8d4-4db0-98ae-990722d6a47f --><ul><li><strong>Consider the need for admission or specialist advice<em>.</em></strong> The decision will depend on clinical judgement, taking into account the person's age, any underlying illness or complications, and the presence of hyperglycaemia (random plasma glucose more than 11 mmol/L) and ketosis.<ul><li><strong>Arrange immediate hospital admission if: </strong><ul><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">diabetic ketoacidosis</a> (DKA). </li><li>There is moderate ketonaemia (1.5–2.9 mmol/L) with or without hyperglycaemia and the person cannot eat or drink, as there is a risk of DKA. </li><li>The child or young person does not improve rapidly with insulin treatment. </li></ul></li><li><strong>Consider arranging hospital admission or seeking urgent specialist advice (depending on clinical judgement) if: </strong><ul><li>The underlying condition is unclear. </li><li>The child or young person is dehydrated or at risk of dehydration. </li><li>Vomiting persists beyond 2 hours (particularly in young children). </li><li>The child is: <ul><li>Becoming exhausted, confused, or dehydrated; is hyperventilating; or has severe abdominal pain. </li><li>Younger than 3 years of age or has a co-existing medical condition.</li></ul></li><li>The child or young person and/or their family/carers are unable to keep the blood glucose level above 3.5 mmol/L. </li><li>The child or young person is on continuous subcutaneous insulin pump therapy. </li><li>The child or young person and/or their family/carers are exhausted, for example due to repeated night-time waking. </li><li>Language problems make it difficult to communicate with the family.</li></ul></li></ul></li><li><strong>If the child or young person can be managed in primary care:</strong><ul><li>Assess and manage the intercurrent illness.</li><li>Assess how well blood glucose has been monitored and managed with diet and insulin.</li><li>Warn the person and/or their family/carers that illness may affect blood glucose control:<ul><li>Some illnesses (especially if associated with fever) can raise blood glucose levels.</li><li>In contrast, illnesses associated with vomiting and diarrhoea (such as gastroenteritis) can lower blood glucose levels, possibly leading to hypoglycaemia (blood glucose levels less than 3.5 mmol/L).</li></ul></li><li><strong>Ensure that the child or young person has:</strong><ul><li>Written <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a> and contact details of the healthcare team.</li><li>Easily digestible food and sugary drinks (to provide energy and to prevent further ketosis).</li><li>Oral rehydration salt sachets (to prevent dehydration, particularly in young children).</li><li>Additional supplies of insulin.</li><li>Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li>A glucagon kit (if appropriate).</li></ul></li></ul></li></ul><!-- end field a3dd2a9a-f8d4-4db0-98ae-990722d6a47f --><!-- end item 1ff2eab3-60fc-45b8-addc-c8a938d90a94 --></div><section aria-labelledby="sick-day-rules" class="ChapterBody-module--wrapper--2HCfk "><h4 id="sick-day-rules">What are the 'sick-day rules' for children and young people with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 10f73bfb-dcde-4afc-8af5-27c0a362bd19 --><!-- begin field a4354bd4-a01b-4d00-b210-861b4fe797f1 --><ul><li><strong>During a period of illness that does not require admission</strong><strong>, remind the child or young person and/or their family/carers to adhere to the 'sick-day rules' that should have been provided by their diabetes team. </strong>They should:<ul><li><strong>Never stop or omit insulin.</strong><ul><li>The dose of insulin may need to be altered during periods of illness; they should seek advice from their diabetes team if they are unsure of how to adjust insulin doses.</li></ul></li><li><strong>Check blood glucose more frequently, for example every 1–2 hours including through the night.</strong><ul><li>The insulin dose should be titrated according to the blood glucose results and the written 'sick-day rules'.</li></ul></li><li><strong>Check for blood ketone levels regularly, for example every 3–4 hours including through the night, and sometimes every 1–2 hours depending on results. </strong><ul><li>Blood ketones should be checked regardless of blood glucose levels. Rarely, ketone levels may be elevated even if blood glucose levels are normal, for example in gastroenteritis</li><li>If the blood ketone level is elevated (greater than 3 mmol/L), they should contact the GP or diabetes care team immediately.</li><li>Advise that the blood ketone testing strips should not be used after the expiry date (as they will not provide a reliable result).</li></ul></li><li><strong>Maintain their normal meal pattern (where possible) if appetite is reduced.</strong><ul><li>Their normal meals could be replaced with carbohydrate-containing drinks (such as milk, milk shakes, fruit juices, and sugary drinks).</li></ul></li><li><strong>Maintain adequate fluid intake to prevent dehydration.</strong><ul><li>Water or sugar-free fluids are probably most appropriate in the majority of cases where blood glucose levels are normal or high.</li><li>If blood glucose levels are low, drinks containing glucose are required (or the person should take carbohydrates if possible).</li><li>Carbonated drinks should be avoided if possible.</li></ul></li><li><strong>Seek urgent medical advice if they are violently sick, drowsy, or unable to keep fluids down.</strong><ul><li>Intravenous fluids may be required.</li></ul></li><li><strong>When feeling better, continue to monitor their blood glucose carefully until it returns to normal.</strong><ul><li>This may take some time.</li><li>Medical advice should be sought if blood glucose remains uncontrolled.</li></ul></li></ul></li><li><strong>Further patient information on managing diabetes during a period of illness is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/" data-hyperlink-id="ae69346e-4409-4f31-9cfe-a9310097fcc0">www.diabetes.org.uk</a>).</strong></li></ul><!-- end field a4354bd4-a01b-4d00-b210-861b4fe797f1 --><!-- end item 10f73bfb-dcde-4afc-8af5-27c0a362bd19 --></div></section><section aria-labelledby="basis-for-recommendation-ddd" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ddd">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ddd79609-5d9e-4b9c-9c78-6399e4b0054d --><!-- begin field 3c7ad581-cfa7-4268-87c1-539f38852f16 --><h5>Managing a period of illness</h5><ul><li>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>], the Association of Children's Diabetes Clinicians and British Society for Paediatric Endocrinology and Diabetes (BSPED) <em>Clinical guideline. Management of type 1 diabetes mellitus during illness in children and young people under 18 years (sick day rules)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>], the <em>ISPAD Clinical Practice Consensus Guidelines 2018: sick day management in children and adolescents with diabetes </em>published by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Laffel, 2018</a>], and the <em>National Service Framework for Children, Young People and Maternity Services – Diabetes Type 1 in childhood and adolescence</em> produced by the Department of Health and Diabetes UK [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2010</a>].</li></ul><h5>'Sick-day rules'</h5><ul><li>NICE did not identify any studies that looked at advice for treating intercurrent illness in children and young people with type 1 diabetes. However, the guideline development group (GDG) agreed that clear and individualized oral and written information on managing intercurrent illness ('sick-day rules') should be offered to children and young people with type 1 diabetes and/or their family/carers. This should include information on monitoring and interpreting blood ketone levels, adjusting insulin regimen, food and fluid intake, and when and where to seek further advice or help. </li><li>CKS has based the recommended 'sick-day rules' on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>], the Association of Children's Diabetes Clinicians and BSPED guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>], the ISPAD consensus guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Laffel, 2018</a>]<em>, </em>and on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/" data-hyperlink-id="2abef3b0-2532-433d-9170-a93100ade64d">www.diabetes.org.uk</a>).</li><li>The recommendation on the frequency of blood glucose monitoring is based on expert opinion in the Association of Children's Diabetes Clinicians and BSPED guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>] and the ISPAD consensus guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Laffel, 2018</a>]<em>.</em></li></ul><h5>Checking blood ketones in children and young people</h5><ul><li>The NICE GDG recommends blood ketone testing (instead of urine ketone testing) in children and young people with type 1 diabetes because:<ul><li>Urine testing is difficult for parents with very young children who are still wearing nappies and, in the GDG's experience, some older children and young people with type 1 diabetes are reluctant to test their urine. </li><li>Blood testing is likely to be more accurate (and allow for more prompt treatment) because it provides a measure of ketone levels at the time of testing, whereas a time lag of a few hours is associated with urine testing while the body processes and excretes the ketones. This is particularly relevant for children and young people on insulin pump therapy because this regimen does not include the use of long-acting insulin; therefore, children and young people using this regimen are more likely to get ketosis quicker. </li></ul></li><li>NICE does not specify how often ketone monitoring should be done. The recommended monitoring frequency is based on what CKS considers to be good clinical practice.</li></ul><h5>Effect of illness on diabetes</h5><ul><li>According to the Association of Children's Diabetes Clinicians and BSPED guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ng, 2018</a>]:<ul><li>Illness generally raises blood glucose levels and increases the risk of ketone body production owing to a relative deficiency of insulin.</li><li>Increased levels of stress hormones during illness contribute to high blood glucose levels.</li><li>Cytokine release in response to infection can also lead to some degree of insulin resistance.</li><li>Diarrhoea and vomiting may reduce blood glucose levels with a possibility of hypoglycaemia rather than hyperglycaemia.</li><li>Ketones may still be produced in significant quantities even with hypoglycaemia in people with gastroenteritis.</li></ul></li></ul><!-- end field 3c7ad581-cfa7-4268-87c1-539f38852f16 --><!-- end item ddd79609-5d9e-4b9c-9c78-6399e4b0054d --></div></section></section><section aria-labelledby="monitoring-for-complications-of-type-1-diabetes" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring-for-complications-of-type-1-diabetes">How should I monitor for complications in children and young people with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e465dc9b-3ec3-46af-b593-51e3ae530ccc --><!-- begin field 817bff0b-4c81-4791-a9bd-116bc9c6effd --><p><strong>Children and young people with type 1 diabetes should have regular surveillance for the complications of type 1 diabetes. The reason for the surveillance as well as the significance of any abnormal findings should be discussed with the person and/or their family/carers. </strong></p><p><strong>Most children and young people with type 1 diabetes are managed in secondary care. </strong></p><ul><li><strong>For a child or young person being managed in primary care, </strong><strong>address the following at every review appointment: </strong><ul><li>Measure HbA1c to ensure adequate blood glucose control. Reiterate <a class="topic-reference internal-reference" href="index.html#target-hba1c">HbA1c</a> and <a class="topic-reference internal-reference" href="index.html#target-glucose-self-monitoring-levels">glucose self-monitoring</a> targets.</li><li>Offer a review of injection sites and address any injection site problems. See the section on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/index.html#managing-injection-site-problems">Managing injection site problems</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-1-diabetes/index.html">Insulin therapy in type 1 diabetes</a> for more information.</li><li>Measure height and weight and plot on an appropriate growth chart. Calculate body mass index (BMI).<ul><li>Check for normal growth and/or significant changes in weight because these may reflect changes in blood glucose control. </li></ul></li><li>Check the smoking status of the child or young person. If applicable, offer smoking cessation advice. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li><li>Assess for psychological problems (such as depression, anxiety, and eating disorders) and social problems (such as alcohol, substance misuse, and relationship problems). <ul><li>Alerting signs include difficulty with self-care and poor blood glucose control (including frequent episodes of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-diabetic-ketoacidosis/index.html">diabetic ketoacidosis</a>). See the section on <a class="topic-reference internal-reference" href="index.html#psychological-social-problems">Psychological and social problems</a> for more information.</li></ul></li></ul></li><li><strong>A</strong><strong>dvise c</strong><strong>hildren and young people with type 1 diabetes and/or their family/carers that they should have:</strong><ul><li>Regular dental examinations, for example every 3–6 months. </li><li>An eye examination by an optometrist every 2 years until the age of 12 years when they will be eligible for the annual <a class="topic-reference internal-reference" href="index.html#eye-disease">diabetes eye screening</a>.</li><li>Their feet assessed for <a class="topic-reference internal-reference" href="index.html#diabetic-foot-problems">diabetic foot problems</a>.</li></ul></li><li><strong>Once a year, offer monitoring for:</strong><ul><li>Moderately increased albuminuria (albumin:creatinine ratio [ACR] 3–30 mg/mmol) to detect <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">diabetic kidney disease</a> (in children aged 12 years and older).</li><li>Hypertension (in children aged 12 years and older).</li><li>Thyroid disease — this should be done at diagnosis and annually thereafter until <a class="topic-reference internal-reference" href="index.html#transition-to-adult-care-services">transfer to adult services</a>.</li></ul></li><li><strong>Be aware of the following possible complications and associated conditions:</strong><ul><li>Juvenille cataracts (rare).</li><li>Necrobiosis lipoidica (a rare skin condition characterized by shiny, red-brown, or yellowish patches, usually on the shins).</li><li>Coeliac disease (this should be screened for at diagnosis). See the CKS topic on <a class="topic-reference external-reference" href="../../../../coeliac-disease.html">Coeliac disease</a> for more information.</li><li>Addison's disease. See the section on <a class="topic-reference external-reference" href="../../../addisons-disease/diagnosis/index.html">Diagnosis</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../addisons-disease/index.html">Addison's disease</a> for information on the clinical features of Addison's disease.</li></ul></li></ul><!-- end field 817bff0b-4c81-4791-a9bd-116bc9c6effd --><!-- end item e465dc9b-3ec3-46af-b593-51e3ae530ccc --></div><section aria-labelledby="psychological-social-problems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="psychological-social-problems">Screening for psychological and social problems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 520b1cb2-20ab-403f-9751-fbcc6e896bba --><!-- begin field afc8ce2b-dfcd-45be-9e2f-48cfc3a6d901 --><p><strong>Children and young people with type 1 diabetes have a greater risk of emotional and behavioural difficulties than children without diabetes.</strong></p><ul><li><strong>When managing a child or young person with type 1 diabetes:</strong><ul><li><strong>If a </strong><strong>behavioural or conduct disorder is suspected,</strong> offer timely access to appropriate mental health professionals. See the CKS topic on <a class="topic-reference external-reference" href="../../../conduct-disorders-in-children-young-people/index.html">Conduct disorders in children and young people</a> for more information.</li><li><strong>If there are family or relationship difficulties, </strong>offer specific family-based behavioural interventions, such as behavioural family systems therapy, if available.</li><li><strong>If there are concerns about psychological wellbeing, </strong>consider referral for a programme of behavioural intervention therapy or behavioural techniques in order to improve: <ul><li>Health-related quality of life, for example counselling or cognitive behavioural therapy (CBT).</li><li>Blood glucose control in children and young people with high HbA1c levels (HbA1c above 69 mmol/mol [8.5%]). </li><li>Adherence to diabetes treatment, for example motivational interviewing or multisystemic therapy (an intensive family- and community-based treatment programme that focuses on addressing all environmental systems that impact chronic and violent juvenile offenders).</li></ul></li><li><strong>If anxiety, depression, or an eating disorder (such as anorexia, bulimia, or <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">diabulimia</a>) is suspected,</strong> refer promptly to child and adolescent mental health services (CAMHS). <ul><li>If there is persistent suboptimal blood glucose control, offer screening for anxiety, depression, and/or eating disorders (which may present with suboptimal overall blood glucose control [both hyperglycaemia and hypoglycaemia] and/or symptoms of gastroparesis). </li><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>, <a class="topic-reference external-reference" href="../../../depression-in-children/index.html">Depression in children</a>, and <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a> for more information on managing these conditions.</li></ul></li></ul></li></ul><!-- end field afc8ce2b-dfcd-45be-9e2f-48cfc3a6d901 --><!-- end item 520b1cb2-20ab-403f-9751-fbcc6e896bba --></div></section><section aria-labelledby="eye-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="eye-disease">Screening for eye disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 966d0b75-8a82-481d-b700-44400d44a333 --><!-- begin field 2a212406-9e47-4639-8a46-b08d184d9866 --><ul><li><strong>A</strong><strong>dvise c</strong><strong>hildren and young people with type 1 diabetes and/or their family/carers that </strong>they should have an eye examination by an optometrist every 2 years until the age of 12 years when they will be eligible for the annual <a href="https://www.gov.uk/guidance/diabetic-eye-screening-programme-overview" data-hyperlink-id="e641f35e-8e71-488a-8623-abc80071381c">NHS diabetic eye screening (DES) programme</a>.<ul><li>The NHS DES is offered once a year to anyone with diabetes who is aged 12 years or over. </li><li>The programme aims to reduce the risk of sight loss among people with diabetes by the early detection and treatment, if needed, of sight-threatening retinopathy.<strong> </strong></li></ul></li><li><strong>Explain to the child or young person and/or their family/carers that: </strong><ul><li>Monitoring for diabetic retinopathy begins at 12 years because diabetic retinopathy that needs treatment is extremely rare in children and young people younger than 12 years of age. </li><li>Background retinopathy is often found through monitoring, and improving blood glucose control will reduce the risk of this progressing to significant diabetic retinopathy.</li><li>Annual monitoring from 12 years of age is important because if significant diabetic retinopathy is found, early treatment will improve the outcome.</li></ul></li><li><strong>Refer children to the local diabetic screening programme prior to their twelfth birthday to ensure that they are seen from 12 years of age.</strong></li></ul><!-- end field 2a212406-9e47-4639-8a46-b08d184d9866 --><!-- end item 966d0b75-8a82-481d-b700-44400d44a333 --></div></section><section aria-labelledby="diabetic-kidney-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diabetic-kidney-disease">Screening for diabetic kidney disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3bd4bb6a-2ed1-4d56-8832-bdfbe6c1e212 --><!-- begin field a3ce25bb-549e-422a-a80b-2f476b39929d --><p><strong>From the age of 12 years, children with type 1 diabetes (with or without detected nephropathy) should receive annual screening for diabetic nephropathy.</strong></p><ul><li><strong>Use the first urine sample of the day ('early morning urine') to measure the albumin:creatinine ratio (ACR).</strong> If this is not possible, use a random sample but be aware that this is associated with an increased risk of false positive results.<ul><li>If the initial ACR is above 3 mg/mmol but below 30 mg/mmol, confirm the result by repeating the test on two further occasions using first urine samples of the day before starting further investigations and therapy.</li><li>If the initial ACR is 30 mg/mmol or more (proteinuria), arrange further investigations. See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li></ul></li><li><strong>Explain to the child or young person and/or their family/carers that:</strong><ul><li>Monitoring for moderately increased albuminuria (ACR 3–30 mg/mmol) to detect diabetic kidney disease begins at 12 years of age because diabetic kidney disease is extremely rare in younger children.</li><li>Using the first urine sample of the day ('early morning urine') to screen for moderately increased albuminuria reduces the risk of false positive results.</li><li>If moderately increased albuminuria is detected, improving blood glucose control will reduce the risk of this progressing to significant diabetic kidney disease.</li><li>Annual monitoring from 12 years is important because if diabetic kidney disease is found, early treatment will improve the outcome. </li></ul></li></ul><!-- end field a3ce25bb-549e-422a-a80b-2f476b39929d --><!-- end item 3bd4bb6a-2ed1-4d56-8832-bdfbe6c1e212 --></div></section><section aria-labelledby="diabetic-foot-problems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diabetic-foot-problems">Screening for diabetic foot problems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5ecd9b46-b45e-46f4-b295-b95804a33ff5 --><!-- begin field 029261fa-d3a9-4013-9f60-57c6c29baf83 --><ul><li><strong>For children with diabetes who are younger than 12 years of age, </strong>give basic foot care advice.</li><li><strong>For young people with diabetes aged between 12–17 years,</strong> ensure that the paediatric care team or the transitional care team assesses their feet as part of their annual assessment, and provide information on foot care. <ul><li>If a diabetic foot problem is found or suspected, the young person should be referred to an appropriate specialist.</li></ul></li></ul><!-- end field 029261fa-d3a9-4013-9f60-57c6c29baf83 --><!-- end item 5ecd9b46-b45e-46f4-b295-b95804a33ff5 --></div></section><section aria-labelledby="basis-for-recommendation-f52" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f52">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f527073b-6cb0-464c-ae6c-2395164ee503 --><!-- begin field e3280445-7bf4-4ba4-9bec-b09b92dca644 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng18/evidence/full-guideline-pdf-435396352" data-hyperlink-id="a80a94c2-5ad3-4d5d-9aaa-a93100c4866c">full NICE guideline</a>.</p><p><strong>Screening for complications</strong> </p><ul><li>Screening for microvascular complications and other complications of type 1 diabetes aims to detect early abnormalities that can potentially be reversed by improved blood glucose control [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li><li>The NICE guideline development group (GDG) states that management strategies for children and young people with type 1 diabetes should include early detection and ongoing treatment of microvascular and other complications. </li></ul><p><strong>Measuring HbA1c </strong></p><ul><li>NICE identified a randomized controlled trial suggesting that tight blood glucose control helps to prevent long-term microvascular complications in young people with type 1 diabetes.</li></ul><h5>Measuring height, weight, and body mass index (BMI)</h5><ul><li>In the expert opinion of NICE, measurement of height and weight is an integral part of diabetes care, and children and young people with optimal blood glucose control are expected to grow and develop normally.</li></ul><h5>Checking smoking status and monitoring for hypertension</h5><ul><li>In the expert opinion of the NICE GDG, macrovascular complications of type 1 diabetes (such as myocardial infarction) are not major concerns for children and young people with type 1 diabetes. However, screening for associated risk factors may help to prevent severe long-term macrovascular complications. </li><li>Dyslipidaemia, sustained hypertension, smoking, and obesity are risk factors for macrovascular disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li></ul><h5>Checking for psychological and social problems</h5><ul><li>Children and young people with type 1 diabetes have a greater risk of emotional and behavioural difficulties than the general population [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].<ul><li>NICE states that although achieving good metabolic control through insulin injections, blood glucose, and dietary monitoring is the cornerstone of diabetes care in preventing both short- and long-term complications, optimal care requires appropriate attention to psychological and social issues that also affect the management and care of type 1 diabetes in children and young people. </li><li>NICE based the recommendations on assessing for, and managing, psychological and social issues in children and young people with type 1 diabetes on available evidence as well as the expert opinion and experience of the GDG.</li></ul></li></ul><h5>Dental screening and eye examination</h5><ul><li>Good dental hygiene should be a part of routine healthcare for all children and young people [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>].<ul><li>NICE found evidence showing a higher prevalence of periodontitis among children and young people with type 1 diabetes compared with children and young people without diabetes, and an association between poor blood glucose control and increased incidence of dental caries in children and young people with type 1 diabetes. </li><li>NICE did not find any evidence on the optimum frequency of routine dental examinations but refers to the NICE guideline on <em>Dental checks: intervals between oral health reviews </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2004</a>], which states that a routine dental examination should be done every 3–12 months for people younger than 18 years of age and every 3–24 months for all other people.</li><li>CKS notes that 6-monthly dental checks have been customary in the General Dental Service in the UK since the start of the NHS. </li></ul></li><li>NICE recommends, based on good clinical practice, that<strong> </strong>children and young people with type 1 diabetes should have an eye examination by an optometrist every 2 years until the age of 12 years when they will be eligible for the annual <a href="https://www.gov.uk/guidance/diabetic-eye-screening-programme-overview" data-hyperlink-id="e641f35e-8e71-488a-8623-abc80071381c">NHS diabetic eye screening (DES) programme</a>.</li></ul><h5>Possible complications and associated conditions</h5><ul><li>Children and young people with type 1 diabetes have a higher prevalence of autoimmune disorders (such as coeliac disease and thyroid disease) than children and young people without type 1 diabetes. Active surveillance for these conditions will help minimize adverse outcomes and complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li><li>The NICE guideline <em>Coeliac disease: recognition, assessment and management</em> states that people with type 1 diabetes should be offered serological testing for coeliac disease at diagnosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015c</a>].</li><li>The definition of necrobiosis lipoidica is taken from a leaflet produced by the British Association of Dermatologists (BAD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BAD, 2019</a>].</li></ul><h5>Monitoring for diabetic kidney disease in children aged 12 years and over</h5><ul><li>Annual monitoring for diabetic kidney disease is important because if this is found, early treatment will improve the outcome [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li></ul><h5>Foot care</h5><ul><li>The recommendations on foot care are based on the NICE guideline <em>Diabetic foot problems: prevention and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>]. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng19/evidence/full-guideline--august-2015-pdf-15672915543" data-hyperlink-id="6ffe0b4b-f81e-4e51-8b4e-a931009895cc">full NICE guideline</a> on diabetic foot problems.</li></ul><!-- end field e3280445-7bf4-4ba4-9bec-b09b92dca644 --><!-- end item f527073b-6cb0-464c-ae6c-2395164ee503 --></div></section></section><section aria-labelledby="transition-to-adult-care-services" class="ChapterBody-module--wrapper--2HCfk "><h3 id="transition-to-adult-care-services">How should I support the transition from paediatric to adult care services?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 28401b39-496a-45a1-957c-151d771f56c0 --><!-- begin field 5749ec23-8d42-473d-9ac8-bdfe754e6df1 --><ul><li><strong>Explain to young people with type 1 diabetes who are preparing for transition to adult services that</strong> <strong>some aspects of diabetes care will change at transition,</strong> for example clinic time and location, diabetes specialist team, and self-monitoring blood glucose targets.</li><li>Detailed information on the transition to adult clinics for young people with type 1 diabetes and their family/carers is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Teens/Me-and-my-diabetes/Transition-to-adult-clinics/" data-hyperlink-id="c8f5097f-fb96-466a-a0ab-a931009b1b50">www.diabetes.org.uk</a>).</li></ul><!-- end field 5749ec23-8d42-473d-9ac8-bdfe754e6df1 --><!-- end item 28401b39-496a-45a1-957c-151d771f56c0 --></div><section aria-labelledby="basis-for-recommendation-905" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-905">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 905fd7bb-0d6e-40c5-87d8-d8bb17b0c529 --><!-- begin field 58829cc0-369a-4a4e-9276-fbee9db63e43 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>] and on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Teens/Me-and-my-diabetes/Transition-to-adult-clinics/" data-hyperlink-id="864a4968-91a0-423c-aac9-a931009d3927">www.diabetes.org.uk</a>).</p><ul><li>NICE states that in young people with type 1 diabetes who are preparing for transition to adult services, clinic attendance rates may be improved by:<ul><li>Allowing sufficient time for the young person to familiarize themselves with the practicalities of the transition.</li><li>Giving appropriate information and advice on what to expect following the transition.</li></ul></li></ul><!-- end field 58829cc0-369a-4a4e-9276-fbee9db63e43 --><!-- end item 905fd7bb-0d6e-40c5-87d8-d8bb17b0c529 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/diabetes-type-1/management/management-children-young-people/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>